|
ILKAP |
ILK associated serine/threonine phosphatase |
|
|
|
|
INPPL1 |
inositol polyphosphate phosphatase like 1 |
- Synthesis of PIPs at the plasma membrane
- Synthesis of IP3 and IP4 in the cytosol
- Interleukin receptor SHC signaling
|
|
|
|
IQGAP1 |
IQ motif containing GTPase activating protein 1 |
- Nephrin family interactions
- Glucagon-like Peptide-1 (GLP1) regulates insulin secretion
- RHO GTPases activate IQGAPs
- MAP2K and MAPK activation
- Neutrophil degranulation
- Signaling by moderate kinase activity BRAF mutants
- Signaling by high-kinase activity BRAF mutants
- Signaling by BRAF and RAF fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- Signaling downstream of RAS mutants
- Signaling by RAF1 mutants
|
|
|
|
IRS1 |
insulin receptor substrate 1 |
- PI3K Cascade
- IRS-mediated signalling
- SOS-mediated signalling
- SOS-mediated signalling
- PIP3 activates AKT signaling
- Interleukin-7 signaling
- PI3K/AKT activation
- PI3K/AKT activation
- Constitutive Signaling by Aberrant PI3K in Cancer
- IRS-related events triggered by IGF1R
- Signaling by Leptin
- RAF/MAP kinase cascade
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- IRS activation
- Signal attenuation
- Activated NTRK3 signals through PI3K
- Growth hormone receptor signaling
|
- [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID
|
|
|
IRS4 |
insulin receptor substrate 4 |
- IRS-related events triggered by IGF1R
|
|
|
|
ITGA5 |
integrin subunit alpha 5 |
- Elastic fibre formation
- Fibronectin matrix formation
- Cell surface interactions at the vascular wall
- Integrin cell surface interactions
- Integrin cell surface interactions
- Signal transduction by L1
- RUNX2 regulates genes involved in cell migration
|
|
|
|
ITGB1 |
integrin subunit beta 1 |
- Elastic fibre formation
- Fibronectin matrix formation
- Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
- Cell surface interactions at the vascular wall
- Basigin interactions
- Molecules associated with elastic fibres
- Integrin cell surface interactions
- Integrin cell surface interactions
- Laminin interactions
- Laminin interactions
- Syndecan interactions
- ECM proteoglycans
- Other semaphorin interactions
- Signal transduction by L1
- Localization of the PINCH-ILK-PARVIN complex to focal adhesions
- CHL1 interactions
- RHO GTPases Activate Formins
- Interleukin-4 and Interleukin-13 signaling
- Platelet Adhesion to exposed collagen
- MET activates PTK2 signaling
- MET interacts with TNS proteins
- HCMV Early Events
- Potential therapeutics for SARS
|
- Antithymocyte immunoglobulin (rabbit)
- MK-0668
|
|
|
ITGB2 |
integrin subunit beta 2 |
- Toll Like Receptor 4 (TLR4) Cascade
- Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
- Cell surface interactions at the vascular wall
- Integrin cell surface interactions
- Interleukin-4 and Interleukin-13 signaling
- Neutrophil degranulation
|
|
- Leukocyte adhesion deficiency (LAD), including the following four diseases: Leukocyte adhesion deficiency (I); Leukocyte adhesion deficiency (II); Leukocyte adhesion deficiency (III); LAD with Rac2 deficiency
|
|
ITK |
IL2 inducible T cell kinase |
- Generation of second messenger molecules
- FCERI mediated Ca+2 mobilization
- FCERI mediated Ca+2 mobilization
|
- Staurosporine
- Pazopanib
- Fostamatinib
- Zanubrutinib
|
|
|
ITSN2 |
intersectin 2 |
- Cargo recognition for clathrin-mediated endocytosis
- Clathrin-mediated endocytosis
|
|
|
|
JAK2 |
Janus kinase 2 |
- Interleukin-6 signaling
- Interleukin-6 signaling
- MAPK3 (ERK1) activation
- MAPK1 (ERK2) activation
- Prolactin receptor signaling
- Prolactin receptor signaling
- Signaling by SCF-KIT
- Signaling by Leptin
- RMTs methylate histone arginines
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- Interleukin-3, Interleukin-5 and GM-CSF signaling
- RAF activation
- RAF/MAP kinase cascade
- Interleukin-4 and Interleukin-13 signaling
- IL-6-type cytokine receptor ligand interactions
- Signaling by moderate kinase activity BRAF mutants
- Signaling by BRAF and RAF fusions
- Paradoxical activation of RAF signaling by kinase inactive BRAF
- Cyclin D associated events in G1
- Interferon gamma signaling
- Regulation of IFNG signaling
- Regulation of IFNG signaling
- Interleukin-20 family signaling
- Interleukin-35 Signalling
- Signaling by Erythropoietin
- Interleukin-12 signaling
- Interleukin-12 signaling
- Interleukin-23 signaling
- Interleukin-23 signaling
- Interleukin-27 signaling
- Interleukin-27 signaling
- Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
- Erythropoietin activates Phosphoinositide-3-kinase (PI3K)
- Erythropoietin activates Phospholipase C gamma (PLCG)
- Erythropoietin activates STAT5
- Erythropoietin activates RAS
- Erythropoietin activates RAS
- Interleukin receptor SHC signaling
- Signaling downstream of RAS mutants
- Signaling by RAF1 mutants
- Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
- Potential therapeutics for SARS
- Growth hormone receptor signaling
- Growth hormone receptor signaling
- Factors involved in megakaryocyte development and platelet production
|
- 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one
- XL019
- 5-phenyl-1H-indazol-3-amine
- 4-(3-amino-1H-indazol-5-yl)-N-tert-butylbenzenesulfonamide
- 4-[(2-{4-[(CYCLOPROPYLCARBAMOYL)AMINO]-1H-PYRAZOL-3-YL}-1H-BENZIMIDAZOL-6-YL)METHYL]MORPHOLIN-4-IUM
- Ruxolitinib
- Tofacitinib
- Baricitinib
- Entrectinib
- Fostamatinib
- Fedratinib
- Zanubrutinib
- Pralsetinib
|
|
|
JUP |
junction plakoglobin |
- Adherens junctions interactions
- VEGFR2 mediated vascular permeability
- Neutrophil degranulation
- Keratinization
- Formation of the cornified envelope
|
|
- Arrhythmogenic right ventricular cardiomyopathy (ARVC)
- Naxos disease and Carvajal syndrome
|
|
KCTD9P2 |
potassium channel tetramerization domain containing 9 pseudogene 2 |
|
|
|
|
KEAP1 |
kelch like ECH associated protein 1 |
- Ub-specific processing proteases
- Neddylation
- Antigen processing: Ubiquitination & Proteasome degradation
|
|
|
|
KRT17 |
keratin 17 |
- Keratinization
- Formation of the cornified envelope
|
|
- Pachyonychia congenita, including: Jadassohn-Lewandowsky syndrome; Jackson-Lawler syndrome ; Steatocystoma multiplex
|
|
KRT18 |
keratin 18 |
- Keratinization
- Formation of the cornified envelope
|
|
|
|
KRT7 |
keratin 7 |
- Keratinization
- Formation of the cornified envelope
|
- Primaquine
- Verpasep caltespen
|
|
|
KRT8 |
keratin 8 |
- Keratinization
- Formation of the cornified envelope
|
- Tenecteplase
- Lanoteplase
- Copper
|
|
|
LAT |
linker for activation of T cells |
- GPVI-mediated activation cascade
- Generation of second messenger molecules
|
|
|
|
LCK |
LCK proto-oncogene, Src family tyrosine kinase |
- GPVI-mediated activation cascade
- PIP3 activates AKT signaling
- Signaling by SCF-KIT
- Signaling by SCF-KIT
- Regulation of KIT signaling
- Nef and signal transduction
- Nef Mediated CD4 Down-regulation
- Downstream TCR signaling
- Phosphorylation of CD3 and TCR zeta chains
- Translocation of ZAP-70 to Immunological synapse
- Generation of second messenger molecules
- PECAM1 interactions
- Constitutive Signaling by Aberrant PI3K in Cancer
- DAP12 signaling
- DAP12 signaling
- CD28 co-stimulation
- CD28 dependent PI3K/Akt signaling
- CD28 dependent Vav1 pathway
- CTLA4 inhibitory signaling
- PD-1 signaling
- PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling
- Interleukin-2 signaling
- Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants
- FLT3 signaling through SRC family kinases
|
- Dasatinib
- AP-22408
- Staurosporine
- 1-Tert-Butyl-3-(4-Chloro-Phenyl)-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine
- {4-[(2S)-2-Acetamido-3-({(1S)-1-[3-carbamoyl-4-(cyclohexylmethoxy)phenyl]ethyl}amino)-3-oxopropyl]-2-phosphonophenoxy}acetic acid
- Phosphoaminophosphonic Acid-Adenylate Ester
- 3-(2-AMINOQUINAZOLIN-6-YL)-4-METHYL-N-[3-(TRIFLUOROMETHYL)PHENYL]BENZAMIDE
- 2,3-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-B]PYRIDIN-4-AMINE
- 5,6-DIPHENYL-N-(2-PIPERAZIN-1-YLETHYL)FURO[2,3-D]PYRIMIDIN-4-AMINE
- N-(2-chlorophenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine
- N-(2,6-dimethylphenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine
- N-(2-chloro-6-methylphenyl)-8-[(3S)-3-methylpiperazin-1-yl]imidazo[1,5-a]quinoxalin-4-amine
- Ponatinib
- Nintedanib
- Fostamatinib
- Zanubrutinib
|
- Combined immunodeficiencies (CIDs), including the following nine diseases: X-linked hyper IgM syndrome; CD40 deficiency hyper IgM syndrome; Purine nucleoside phosphorylase (PNP) deficiency; Omenn syndrome; MHC deficiency (HLA-class I); MHC deficiency (HLA-class II); Zap-70 deficiency; p56 Lck deficiency; CD8 deficiency
|